Retroviral particles are effectively purified on an affinity matrix containing peptides selected by phage-display.

Cláudia S M Fernandes, Inês Barbosa, Rute Castro, Ana Sofia Pina, Ana Sofia Coroadinha, Ana Barbas, A Cecília A Roque

Journal: Biotechnology journal 2017;11(12):1513-1524

PMID: 27491899

Abstract

Retroviral particles are expensive to manufacture, mostly due to the downstream processing steps which result in low recoveries (≈30%) and concentration factors. In this work, a dodecapeptide phage-display library was panned against retrovirus like particles expressing the envelope protein Ampho4070A (VLPs-AMPHO) and VLPs without the target protein, used as a negative control (VLPs). A depletion/selection panning protocol was successfully used to deal with the structural complexity of the target, and a total of three distinct peptide sequences displaying preferential binding towards VLPs-AMPHO were found. Peptide 3 (CAAALAKPHTENHLLT), which appeared as one lead candidate, was synthesized and immobilized onto two purification matrices, cross-linked agarose and magnetic particles. The matrices selectively bound VLPs-AMPHO and in both cases recovery yields higher than 90% were obtained when employing mild elution conditions, while maintaining viral particle morphology and size.

Copyright © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Address: UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnológia, Universidade Nova de Lisboa, Caparica, Portugal.; iBET, Instituto de Biologia Experimental e Tecnológia, Oeiras, Portugal.; Instituto de Tecnológia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.; Bayer Portugal, S.A., Carnaxide, Portugal.

Link outs

Free resources

Other Literature Sources:

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.